search button

Downregulation of microRNA-139 is associated with hepatocellular carcinoma risk and short-term survival

  • Authors:
    • Tao Li
    • Jikai Yin
    • Lijuan Yuan
    • Shouli Wang
    • Lin Yang
    • Xilin Du
    • Jianguo Lu

  • View Affiliations

  • Published online on: February 19, 2014     https://doi.org/10.3892/or.2014.3032
  • Pages: 1699-1706
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MicroRNAs (miRNAs) have been frequently reported to be diagnostic biomarkers and prognostic factors for cancer. The aim of the present study was to evaluate the clinical significance of microRNA-139 (miRNA-139) in hepatocellular carcinoma (HCC). All 31 patients enrolled in the present study had received curative hepatectomy. The objective miRNA was determined using miRNA microarray. The miRNA-139 expression level in cancerous tissue specimens was measured by means of reverse transcription and quantitative polymerase chain reaction, and compared with that in 31 corresponding peritumoral non-cancerous tissues. Plasma miRNA-139 expression was also quantified. The diagnostic value of plasma miRNA-139 for differentiating patients with HCC from the ones with chronic HBV-hepatitis (CH) was analyzed. The miRNA microarray performed in 3 pairs of tissue specimens determined miRNA-139 was downregulated (p=0.017). Compared with plasma of chronic HBV-hepatitis, miRNA-139 was lowly expressed in plasma of HCC patients (p<0.010). ROC analysis of plasma miRNA-139 yielded an AUC of 0.764 (p<0.010) with sensitivity of 80.6% and specificity of 58.1% while differentiating HCC from chronic HBV-hepatitis. The diagnostic power of serum α-fetoprotein (AFP) was also evaluated. The combination of miRNA-139 and AFP improved the differentiating power. Subsequently, 31 HCC patients were divided into the low or high expression group based on plasma miRNA-139 level. Plasma miRNA‑139 expression was correlated with serum AFP (p=0.043), Edmondson-Steiner grading (p=0.038). In addition, there was a significant difference in the 1-year survival rates between the two groups (p=0.023). miRNA‑139 was downregulated in the cancerous tissue and plasma of HCC patients. Plasma miRNA‑139 is a diagnostic biomarker and prognostic factor for HCC.
View Figures
View References

Related Articles

Journal Cover

2014-April
Volume 31 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 3.8
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 8.5
  • CiteScore Rank: Q1: #74/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.719
  • SCImago Journal Rank (SJR): 0.864
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Li T, Yin J, Yuan L, Wang S, Yang L, Du X and Lu J: Downregulation of microRNA-139 is associated with hepatocellular carcinoma risk and short-term survival. Oncol Rep 31: 1699-1706, 2014.
APA
Li, T., Yin, J., Yuan, L., Wang, S., Yang, L., Du, X., & Lu, J. (2014). Downregulation of microRNA-139 is associated with hepatocellular carcinoma risk and short-term survival. Oncology Reports, 31, 1699-1706. https://doi.org/10.3892/or.2014.3032
MLA
Li, T., Yin, J., Yuan, L., Wang, S., Yang, L., Du, X., Lu, J."Downregulation of microRNA-139 is associated with hepatocellular carcinoma risk and short-term survival". Oncology Reports 31.4 (2014): 1699-1706.
Chicago
Li, T., Yin, J., Yuan, L., Wang, S., Yang, L., Du, X., Lu, J."Downregulation of microRNA-139 is associated with hepatocellular carcinoma risk and short-term survival". Oncology Reports 31, no. 4 (2014): 1699-1706. https://doi.org/10.3892/or.2014.3032